GlassScriptPhysician profile
John T Adkins
NPI 1821040395
$4,215.52
in general payments reported to CMS, 2019-2025
35 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $650 · 2020: $234 · 2021: $601 · 2022: $831 · 2023: $725 · 2024: $797 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,814 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,814.44 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $534.87 | 2019-2023 | Orilissa, Lo Loestrin Fe |
| Shield Therapeutics INC | $479.16 | 2023-2025 | Accrufer |
| Gynesonics, INC. | $298.01 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Exeltis, USA INC. | $271.94 | 2020-2024 | Slynd |
| Inari Medical, INC. | $199.24 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Bayer Healthcare Pharmaceuticals INC. | $189.24 | 2019-2025 | |
| Lupin INC. | $177.17 | 2019-2021 | |
| Stryker Corporation | $173.97 | 2025 | Clottriever Bold Catheter |
| Pfizer INC. | $148.49 | 2019-2024 | |
| Aspira Women'S Health INC | $143.37 | 2022-2024 | Ova1 |
| Astellas Pharma US INC | $139.64 | 2019-2024 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $124.55 | 2020-2022 | |
| Sage Therapeutics, LLC | $118.49 | 2023-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $102.16 | 2021-2023 | |
| Therapeuticsmd, INC. | $100.42 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $100.33 | 2019-2020 | |
| Medtronic, INC. | $95.33 | 2021-2022 | |
| Myovant Sciences INC. | $89.55 | 2021-2022 | |
| Avion Pharmaceuticals | $87.69 | 2019-2023 | Balcoltra |
| Agile Therapeutics, INC. | $86.95 | 2021-2023 | Twirla |
| Avanos Medical | $82.47 | 2019 | |
| Mylan Pharmaceuticals INC. | $59.36 | 2021-2022 | |
| Organon LLC | $56.82 | 2021-2025 | Nexplanon |
| Coopersurgical, INC. | $52.10 | 2019-2023 | Paragard T 380a |
| Roche Diagnostics Corporation | $49.12 | 2019-2020 | |
| Channel Medsystems, INC. | $48.42 | 2023 | |
| Sumitomo Pharma America, INC. | $35.63 | 2023-2025 | Myfembree |
| Allergan, INC. | $28.70 | 2020 | |
| Davol INC. | $27.60 | 2023 | Arista Ah Flexitip |
| Merck Sharp & Dohme LLC | $27.03 | 2019 | |
| Duchesnay USA Incorporated | $22.37 | 2019 | |
| Olympus America INC. | $19.64 | 2023 | Olympus, Endoeye Flex Deflectable Videoscope |
| Lilly USA, LLC | $17.20 | 2025 | Zepbound |
| Evofem Biosciences, INC. | $17.15 | 2022 | |
| Ethicon US, LLC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Adkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.